[
  {
    "ts": null,
    "headline": "Challenges pharma companies face in push into US manufacturing",
    "summary": "Yahoo Finance senior health reporter Anjalee Khemlani explains the pharmaceutical industry's push into domestic manufacturing in the US, as a reshoring tactic to tighten up the supply chain. Planning can still take several years to be finalized and face cost barriers amid tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=647e80b2671926a3baa104ef7f96ea131e061c75f5c4734f3312c9e5b565dc4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749240997,
      "headline": "Challenges pharma companies face in push into US manufacturing",
      "id": 135082821,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Yahoo Finance senior health reporter Anjalee Khemlani explains the pharmaceutical industry's push into domestic manufacturing in the US, as a reshoring tactic to tighten up the supply chain. Planning can still take several years to be finalized and face cost barriers amid tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=647e80b2671926a3baa104ef7f96ea131e061c75f5c4734f3312c9e5b565dc4d"
    }
  },
  {
    "ts": null,
    "headline": "AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement",
    "summary": "AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight its potential. Click for my ANAB update.",
    "url": "https://finnhub.io/api/news?id=e2a1528124fcb823bf81c26a72d12eaf2522f65bca901d1be86ee52af6ef1edf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749224369,
      "headline": "AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement",
      "id": 135081764,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2211289162/image_2211289162.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight its potential. Click for my ANAB update.",
      "url": "https://finnhub.io/api/news?id=e2a1528124fcb823bf81c26a72d12eaf2522f65bca901d1be86ee52af6ef1edf"
    }
  },
  {
    "ts": null,
    "headline": "Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?",
    "summary": "We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE:BMY) stands against other stocks that Jim Cramer discusses. In an older segment, a long-time listener asked about Bristol-Myers Squibb Co. (NYSE:BMY) given its dividend and drug […]",
    "url": "https://finnhub.io/api/news?id=a81c4cc3629befdd7fd0dca2fa0be2d63b5d403537b013cfb94ec040610942c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749217290,
      "headline": "Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?",
      "id": 135074200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE:BMY) stands against other stocks that Jim Cramer discusses. In an older segment, a long-time listener asked about Bristol-Myers Squibb Co. (NYSE:BMY) given its dividend and drug […]",
      "url": "https://finnhub.io/api/news?id=a81c4cc3629befdd7fd0dca2fa0be2d63b5d403537b013cfb94ec040610942c5"
    }
  },
  {
    "ts": null,
    "headline": "Was Jim Cramer Right About Pfizer Inc. (PFE)?",
    "summary": "We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. In that older episode, a viewer asked whether it was time to sell or hold shares of Pfizer Inc. […]",
    "url": "https://finnhub.io/api/news?id=aacb658b51368ce646c9169b5abaf73b14593b43b510019a454a46afe18a2b00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749217223,
      "headline": "Was Jim Cramer Right About Pfizer Inc. (PFE)?",
      "id": 135083134,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. In that older episode, a viewer asked whether it was time to sell or hold shares of Pfizer Inc. […]",
      "url": "https://finnhub.io/api/news?id=aacb658b51368ce646c9169b5abaf73b14593b43b510019a454a46afe18a2b00"
    }
  },
  {
    "ts": null,
    "headline": "BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?",
    "summary": "BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure",
    "url": "https://finnhub.io/api/news?id=8bdf08aa6b9dd3b55b16632cb2f779e01b35ade0db84fb1f1e72ed9419c7ad8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749215760,
      "headline": "BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?",
      "id": 135079537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure",
      "url": "https://finnhub.io/api/news?id=8bdf08aa6b9dd3b55b16632cb2f779e01b35ade0db84fb1f1e72ed9419c7ad8d"
    }
  },
  {
    "ts": null,
    "headline": "Humana: Implied Volatility Creating A Viable Investment Case",
    "summary": "Humana: Implied Volatility Creating A Viable Investment Case",
    "url": "https://finnhub.io/api/news?id=757989e823efd9e069f49d41fb3c84d09a9b1af3c2b3471fddc876348cf761c7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749209287,
      "headline": "Humana: Implied Volatility Creating A Viable Investment Case",
      "id": 135079751,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=757989e823efd9e069f49d41fb3c84d09a9b1af3c2b3471fddc876348cf761c7"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer",
    "summary": "– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of",
    "url": "https://finnhub.io/api/news?id=30446cdcceb4ff62812bad5bf52bb26bbe0487a92367cd80ed4d917d9315f41c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749207600,
      "headline": "Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer",
      "id": 135072824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of",
      "url": "https://finnhub.io/api/news?id=30446cdcceb4ff62812bad5bf52bb26bbe0487a92367cd80ed4d917d9315f41c"
    }
  },
  {
    "ts": null,
    "headline": "Zacks.com featured highlights JAKKS Pacific, Green Dot, Signet Jewelers, Gibraltar Industries and Pfizer",
    "summary": "JAKK, GDOT, SIG, ROCK, and PFE offer low P/S ratios and high growth potential, making them standout value plays now.",
    "url": "https://finnhub.io/api/news?id=006ccd2cef663612f2ab869a14a4ac894072a2faa53a2ad0384ad35f1b0a9e87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749201300,
      "headline": "Zacks.com featured highlights JAKKS Pacific, Green Dot, Signet Jewelers, Gibraltar Industries and Pfizer",
      "id": 135072827,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "JAKK, GDOT, SIG, ROCK, and PFE offer low P/S ratios and high growth potential, making them standout value plays now.",
      "url": "https://finnhub.io/api/news?id=006ccd2cef663612f2ab869a14a4ac894072a2faa53a2ad0384ad35f1b0a9e87"
    }
  },
  {
    "ts": null,
    "headline": "Buy 7 Ideal 'Safer' May Dividends, Out Of 40 Reader Tags",
    "summary": "Discover high-yield stocks with my yield-based 'dogcatcher' strategy. Explore May 2025 ReFa/Ro Dogs offering up to 83.4% growth potential.",
    "url": "https://finnhub.io/api/news?id=1c0bee6f32a9f7deb4466f12e8d159569f9c4964e1b67c2202b66f421babbc57",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749200509,
      "headline": "Buy 7 Ideal 'Safer' May Dividends, Out Of 40 Reader Tags",
      "id": 135071707,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/948623670/image_948623670.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover high-yield stocks with my yield-based 'dogcatcher' strategy. Explore May 2025 ReFa/Ro Dogs offering up to 83.4% growth potential.",
      "url": "https://finnhub.io/api/news?id=1c0bee6f32a9f7deb4466f12e8d159569f9c4964e1b67c2202b66f421babbc57"
    }
  },
  {
    "ts": null,
    "headline": "Thornburg Investment Income Builder Fund Q1 2025 Commentary",
    "summary": "Thornburg Investment Income Builder Fund paid ordinary dividends of $0.24 per I share during Q1â2025, flat versus Q1â24.",
    "url": "https://finnhub.io/api/news?id=2589f9383cf86d7b276d5c426087bc24e124f08c5af2d3d742853c7cad213f70",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749198600,
      "headline": "Thornburg Investment Income Builder Fund Q1 2025 Commentary",
      "id": 135071429,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155369212/image_155369212.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Thornburg Investment Income Builder Fund paid ordinary dividends of $0.24 per I share during Q1â2025, flat versus Q1â24.",
      "url": "https://finnhub.io/api/news?id=2589f9383cf86d7b276d5c426087bc24e124f08c5af2d3d742853c7cad213f70"
    }
  },
  {
    "ts": null,
    "headline": "With ADCs on the rise, drugmakers embrace a new oncology pillar",
    "summary": "A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.",
    "url": "https://finnhub.io/api/news?id=3a2827d7e702430f1148456fc5e62e1a8910557f19ee8a759dbc1ebf6de7868d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749196800,
      "headline": "With ADCs on the rise, drugmakers embrace a new oncology pillar",
      "id": 135083136,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.",
      "url": "https://finnhub.io/api/news?id=3a2827d7e702430f1148456fc5e62e1a8910557f19ee8a759dbc1ebf6de7868d"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas, Pfizer Seek FDA Approval of Vepdegestrant in Breast Cancer",
    "summary": "Arvinas, Pfizer Seek FDA Approval of Vepdegestrant in Breast Cancer",
    "url": "https://finnhub.io/api/news?id=3cc86edff3dca629a7f0d28ac31909ae1d746afca45b4a59c99601959e56c8ff",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749196320,
      "headline": "Arvinas, Pfizer Seek FDA Approval of Vepdegestrant in Breast Cancer",
      "id": 135075446,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Arvinas, Pfizer Seek FDA Approval of Vepdegestrant in Breast Cancer",
      "url": "https://finnhub.io/api/news?id=3cc86edff3dca629a7f0d28ac31909ae1d746afca45b4a59c99601959e56c8ff"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment",
    "summary": "Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I like BMY more than BNTX.",
    "url": "https://finnhub.io/api/news?id=40cf75ca9897f3bf3f3b4d289a9e6137b5c5103261433b512c310964b73f87be",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749193200,
      "headline": "Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment",
      "id": 135070790,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160008492/image_2160008492.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I like BMY more than BNTX.",
      "url": "https://finnhub.io/api/news?id=40cf75ca9897f3bf3f3b4d289a9e6137b5c5103261433b512c310964b73f87be"
    }
  },
  {
    "ts": null,
    "headline": "Despite Trade War, U.S. Drug Companies Turn to China for Key Cancer Treatments",
    "summary": "Despite Trade War, U.S. Drug Companies Turn to China for Key Cancer Treatments",
    "url": "https://finnhub.io/api/news?id=77a67bf0c113733b93403a0745a49aae374fe4d781ff3028768ff41898a41519",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749173400,
      "headline": "Despite Trade War, U.S. Drug Companies Turn to China for Key Cancer Treatments",
      "id": 135072336,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Despite Trade War, U.S. Drug Companies Turn to China for Key Cancer Treatments",
      "url": "https://finnhub.io/api/news?id=77a67bf0c113733b93403a0745a49aae374fe4d781ff3028768ff41898a41519"
    }
  }
]